SCHEMBL16446627

SCHEMBL16446627

CCc1nc(Cl)nc2c1ccn2-c1cccc(OCC(=O)N(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.50
▸ MAT2A P31153 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ACSS2 Q9NR19 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MAP3K14 Q99558 1/20 0.35
▸ GPBAR1 Q8TDU6 1/20 0.35
▸ GABRA2 P47869 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ FAAH O00519 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CCKAR P32238 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19119122 0.85 PDE4B (0.51) PDE4BMAT2ASMN1; SMN2ACSS2KDM4E
SCHEMBL17784221 0.85 PDE4B (0.57) PDE4BMAT2ASMN1; SMN2ACSS2KDM4E
SCHEMBL19119085 0.84 PDE4B (0.57) PDE4BMAT2ASMN1; SMN2ACSS2KDM4E
SCHEMBL19118428 0.84 PDE4B (0.55) PDE4BSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL19119081 0.84 PDE4B (0.54) PDE4BMAT2ATP53RAB9A
SCHEMBL17784213 0.83 PDE4B (0.57) PDE4BKDM4EHSD17B10
SCHEMBL19119137 0.82 PDE4B (0.49) PDE4BALDH1A1TP53
SCHEMBL17784212 0.81 PDE4B (0.48) PDE4BSMN1; SMN2ACSS2KDM4EALDH1A1
SCHEMBL17784227 0.81 PDE4B (0.54) PDE4BRAB9A
SCHEMBL16448100 0.81 PDE4B (0.58) PDE4BMAT2ASMN1; SMN2HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885MAT2A 1307/4885SMN1; SMN2 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback